Impacts of Estrogen Receptor,Progesterone Receptor and Human Epidermal Growth Factor Receptor-2 Status on Chemotherapy Effects in Breast Cancer

Lu-xing ZHONG,Wen-yan CHEN,Zheng-yu ZHAN
DOI: https://doi.org/10.3969/j.issn.1000-2294.2010.05.016
2010-01-01
Abstract:Objective To investigate the impacts of estrogen receptor(ER),progesterone receptor(PgR) and human epidermal growth factor receptor-2(HER-2) status on chemotherapy effects in breast cancer.Methods Forty-six female advanced breast cancer cases were analyzed.Among them,estrogen receptor(ER) was negative in 14 cases,positive in 18(+ 8, 5 and  5) and unknown in 14;Progesterone receptor(PgR) was negative in 9 cases,positive in 23(+ 10, 9 and  4) and unknown in 14;Human epidermal growth factor receptor-2(HER-2) was negative in 8 cases,positive in 21(+ 6, 9 and  6) and unknown in 17.All the patients received chemotherapy regimen(paclitaxel combined pirarubicin(THP),or docetaxel combined with THP,or docetaxel combined with cisplatin).Results Of the 43 cases with effective estimate,complete response(CR) was received in 4,partial response(PR) in 21,stable of disease(SD) in 12 and progress of disease(PD) in 6.The response rate were,respectively,55.6% and 41.7% in ER positive and negative group,50.0% and 50.0% in PgR positive and negative group and 50.0% and 42.9% in HER-2 positive and negative group,and there was no statistical significance between positive group and negative group(all P>0.05).Grade 3 neutropenia was observed in 5 patients,grade 4 neutropenia in 3,grade 3 alopecia in 12 and grade 3 nausea or vomiting in 9.Conclusion The status of ER,PgR and HER-2 can not affect chemotherapy effects in breast cancer.
What problem does this paper attempt to address?